Clinical Benefits of Sodium–Glucose Cotransporter 2 Inhibitors and the Mechanisms Underlying Their Cardiovascular Effects

In addition to showing antidiabetic effects, sodium–glucose cotransporter 2 (SGLT2) inhibitors also reduce cardiovascular events in patients with type 2 diabetes mellitus. In major trials of cardiovascular outcomes, SGLT2 inhibitors have been shown to improve cardiovascular and renal outcomes, inclu...

Descripción completa

Detalles Bibliográficos
Autores principales: Kubota, Yoshiaki, Shimizu, Wataru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
State-of-the-Art Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627935/
https://www.ncbi.nlm.nih.gov/pubmed/36338417
http://dx.doi.org/10.1016/j.jacasi.2022.03.009
_version_ 1784823085754482688
author Kubota, Yoshiaki
Shimizu, Wataru
author_facet Kubota, Yoshiaki
Shimizu, Wataru
author_sort Kubota, Yoshiaki
collection PubMed
description In addition to showing antidiabetic effects, sodium–glucose cotransporter 2 (SGLT2) inhibitors also reduce cardiovascular events in patients with type 2 diabetes mellitus. In major trials of cardiovascular outcomes, SGLT2 inhibitors have been shown to improve cardiovascular and renal outcomes, including reduced rehospitalization in patients with heart failure, regardless of the presence of diabetes. A recent report showed that the benefits of SGLT2 inhibitors in terms of cardiovascular deaths/admissions caused by heart failure and reduced ejection fraction were greater in Asians than in Whites. In this review, the first part demonstrates the results of recent clinical trials and their clinical implications and outlines current trials and upcoming research areas. The second part provides a general overview of the current understanding of the mechanisms of the cardiovascular benefits of SGLT2 inhibitors.
format Online
Article
Text
id pubmed-9627935
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-96279352022-11-04 Clinical Benefits of Sodium–Glucose Cotransporter 2 Inhibitors and the Mechanisms Underlying Their Cardiovascular Effects Kubota, Yoshiaki Shimizu, Wataru JACC Asia State-of-the-Art Review In addition to showing antidiabetic effects, sodium–glucose cotransporter 2 (SGLT2) inhibitors also reduce cardiovascular events in patients with type 2 diabetes mellitus. In major trials of cardiovascular outcomes, SGLT2 inhibitors have been shown to improve cardiovascular and renal outcomes, including reduced rehospitalization in patients with heart failure, regardless of the presence of diabetes. A recent report showed that the benefits of SGLT2 inhibitors in terms of cardiovascular deaths/admissions caused by heart failure and reduced ejection fraction were greater in Asians than in Whites. In this review, the first part demonstrates the results of recent clinical trials and their clinical implications and outlines current trials and upcoming research areas. The second part provides a general overview of the current understanding of the mechanisms of the cardiovascular benefits of SGLT2 inhibitors. Elsevier 2022-06-07 /pmc/articles/PMC9627935/ /pubmed/36338417 http://dx.doi.org/10.1016/j.jacasi.2022.03.009 Text en © 2022 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle State-of-the-Art Review
Kubota, Yoshiaki
Shimizu, Wataru
Clinical Benefits of Sodium–Glucose Cotransporter 2 Inhibitors and the Mechanisms Underlying Their Cardiovascular Effects
title Clinical Benefits of Sodium–Glucose Cotransporter 2 Inhibitors and the Mechanisms Underlying Their Cardiovascular Effects
title_full Clinical Benefits of Sodium–Glucose Cotransporter 2 Inhibitors and the Mechanisms Underlying Their Cardiovascular Effects
title_fullStr Clinical Benefits of Sodium–Glucose Cotransporter 2 Inhibitors and the Mechanisms Underlying Their Cardiovascular Effects
title_full_unstemmed Clinical Benefits of Sodium–Glucose Cotransporter 2 Inhibitors and the Mechanisms Underlying Their Cardiovascular Effects
title_short Clinical Benefits of Sodium–Glucose Cotransporter 2 Inhibitors and the Mechanisms Underlying Their Cardiovascular Effects
title_sort clinical benefits of sodium–glucose cotransporter 2 inhibitors and the mechanisms underlying their cardiovascular effects
topic State-of-the-Art Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627935/
https://www.ncbi.nlm.nih.gov/pubmed/36338417
http://dx.doi.org/10.1016/j.jacasi.2022.03.009
work_keys_str_mv AT kubotayoshiaki clinicalbenefitsofsodiumglucosecotransporter2inhibitorsandthemechanismsunderlyingtheircardiovasculareffects
AT shimizuwataru clinicalbenefitsofsodiumglucosecotransporter2inhibitorsandthemechanismsunderlyingtheircardiovasculareffects

Ejemplares similares